Foundations

Profhilo, Rejuran, Skinvive and NCTF: what each kind of skinbooster is made of

Dr Ong Jin Khang · MMC 45245 · LCP holder · The Retreat Clinic, Setia Alam

Skinbooster is a general word for injections placed in the skin, and the names behind it fall into three groups. Skinvive (cross-linked hyaluronic acid), Restylane Vital (stabilised hyaluronic acid) and Profhilo (hyaluronic acid of two molecular weights, which its maker describes as stabilised by heat rather than by a chemical cross-linker) are hyaluronic acid products. Rejuran belongs to the polynucleotides, purified DNA fragments that are usually taken from salmon or trout. NCTF, Sunekos and Jalupro are cocktails, hyaluronic acid with other ingredients added. The trial evidence is limited in every group, with modest numbers, follow-up of months rather than years and, in several trials, the maker as funder.

A watercolour of skin layers in pink and sand shades enclosing a pool of pale turquoise water with small bubbles and a single green leaf floating in it. Illustration, not a photograph.

Skinbooster names sort into three groups, and each group comes with its own limited evidence.

On this page
  1. What is a skinbooster?
  2. Hyaluronic acid skinboosters: Skinvive, Restylane Vital and Profhilo
  3. Polynucleotides and PDRN: Rejuran and the salmon injections
  4. Cocktail products: NCTF, Sunekos and Jalupro
  5. What to ask before any skinbooster

In short

  • Skinbooster is a general word for injections placed in the skin, and the names behind it fall into three groups.
  • Skinvive (cross-linked hyaluronic acid), Restylane Vital (stabilised hyaluronic acid) and Profhilo (hyaluronic acid of two molecular weights, which its maker describes as stabilised by heat rather than by a chemical cross-linker) are hyaluronic acid products.
  • Rejuran belongs to the polynucleotides, purified DNA fragments that are usually taken from salmon or trout.
  • NCTF, Sunekos and Jalupro are cocktails, hyaluronic acid with other ingredients added.
  • The trial evidence is limited in every group, with modest numbers, follow-up of months rather than years and, in several trials, the maker as funder.

What is a skinbooster?

Skinbooster names a purpose and covers several ingredients: the 2023 systematic review used later in this article included eight studies of hyaluronic acid alone and five of hyaluronic acid with other active ingredients. What skinboosters share is the method, small amounts placed at many points in the dermis, the layer beneath the surface, to improve skin quality such as hydration, texture and fine lines. The article on what skinboosters fix, and what they never will covers what to expect.

The names people ask about sort into three groups: hyaluronic acid on its own, in stabilised or high-concentration forms; polynucleotides (PN), which include PDRN; and cocktails of hyaluronic acid with other ingredients. In Malaysia these products are regulated as medical devices, and each can be searched on the Medical Device Authority's public register at mdar.mda.gov.my. An entry shows that a device is registered. It says nothing about whether the product works. One newer name, RE20 (Elravie Re2O), is a different kind of product again, made from donated human skin, and what it is and what the one published trial found is set out separately. The regulation hub sets out how the registers fit together.

FeatureHyaluronic acidPolynucleotides (PN, PDRN)Cocktail products
ExamplesSkinvive, Restylane Vital, ProfhiloRejuran, Plinest, NucleofillNCTF 135 HA, Sunekos, Jalupro
What it isHyaluronic acid on its own, in stabilised or high-concentration formsPurified DNA fragments, usually from salmon or troutHyaluronic acid mixed with other ingredients
EvidenceA 2023 review of 13 studies found better hydration, firmness and textureA 2026 review found seven trials with 183 participantsReview draws mainly on laboratory studies of cells
What to mentionAllergy to lidocaine or bacterial proteins matters for some gelsFish allergy mattersNot stated
The three groups of skinbooster compared, summarising the text and sources of this article.

Hyaluronic acid skinboosters: Skinvive, Restylane Vital and Profhilo

Skinvive is cross-linked hyaluronic acid (HA) at 12 mg/mL with a little lidocaine, made for injection into the dermis; the FDA's summary says it is marketed as Juvéderm Volite outside the United States. Restylane Vital, in the Restylane Skinboosters range, is described on the Malaysian register as stabilised HA of non-animal origin, injected in the dermal layer. Profhilo's register entry describes highly purified HA in two molecular weights, 32 mg of each in a 2 mL syringe, and a higher-concentration version, Profhilo Structura, holds 45 mg of each. A 2022 paper by authors who work for its maker describes these as heat-stabilised hybrid complexes, a different class from chemically cross-linked gels.

The trial behind Skinvive's US approval randomised 209 adults to cheek treatment or a delayed-treatment control. The evaluator was blinded, the participants were not, and the maker ran the study. One month after treatment, 57.9% of the treated group and 4.5% of controls had improved by at least one grade on a cheek smoothness scale; at six months, 55.6% of treated participants were still responders, with no untreated group left for comparison.

For Profhilo, a small triple-blind split-face trial in 12 women compared it with saline around the mouth. Imaging showed improvement in wrinkles and pores, but on ultrasound the dermal thickness rose on both sides, and the authors concluded that the effect on thickness did not exceed the placebo effect and that participants were not fully satisfied with the outcomes. In a 24-woman split-face study of Profhilo against another HA skinbooster, both improved hydration and elasticity from baseline and did not differ significantly over 14 weeks. For Restylane Vital, the study read for this article had 30 women and no control group, so it cannot show what the injections themselves changed. A 2023 systematic review of 13 studies of injectable HA for facial skin quality found improvement in hydration, firmness and texture, and called for large randomised trials. None of these results can be laid side by side, because the products, areas, comparators and measures all differ.

Disclosure: in September 2026 I received the 2025 IBSA Key Opinion Leader Award; IBSA makes Profhilo.

Polynucleotides and PDRN: Rejuran and the salmon injections

Polynucleotide (PN) products, such as Rejuran, Plinest and Nucleofill, contain purified DNA fragments, and in this group the DNA is usually taken from the gonads of salmon or trout. PN is the wider group; PDRN is a subset with smaller fragments, and the two names are often used interchangeably. The Malaysian register lists Rejuran, Rejuran I and Rejuran S as one family, at 20 mg/mL of highly purified sodium polynucleotides for injection in the mid to deep dermis, and a separate entry, Rejuran HB Plus, combines polynucleotide with hyaluronic acid.

The proposed mechanisms are binding to the adenosine A2A receptor and supplying DNA building blocks to stressed cells. A narrative review in the Journal of Cutaneous and Aesthetic Surgery cites many laboratory studies of cultured cells behind them. How far they hold in human skin is for trials to show, and the randomised evidence is small. A 2026 systematic review found seven trials with 183 participants, four of them in skin rejuvenation, and none of those four compared an injected polynucleotide with an injected placebo; they compared delivery methods, formulations or an add-on to another treatment. The review found no serious treatment-related adverse events, and noted small samples, varied protocols and varied outcome measures.

Among its limitations, the narrative review lists few standardised protocols and variation between batches from the same source, and it notes that no data yet cover long-term evaluation. It advises caution in anyone with hypersensitivity to fish, so mention a fish allergy before treatment. The register entry for Rejuran also states that only a physician may use it and that it is not for children, adolescents, or pregnant or breastfeeding women. The article on PDRN, polynucleotides and salmon DNA goes further into the evidence, and exosomes, another emerging category, have an article of their own.

Cocktail products: NCTF, Sunekos and Jalupro

The third group mixes HA with other ingredients. The register describes NCTF 135 HA as free, non-cross-linked HA in a solution called NCTF, which a 2015 review, written with help paid for by the company that markets it, describes as containing vitamins, minerals, amino acids, nucleotides, coenzymes and antioxidants. Sunekos and Jalupro pair sodium hyaluronate with amino acids. The idea, often called biorevitalisation or polycomponent mesotherapy, is to supply raw materials that skin fibroblasts are said to use.

That review draws mainly on laboratory studies of cells, and calls for large, well-controlled clinical trials. One randomised trial of NCTF 135 HA, funded by the maker, enrolled 146 people and compared injections plus a moisturiser with the moisturiser alone. At day 75 and day 120, superficial wrinkles had reduced more in the injected group, but the control group had no injected placebo. The 2023 systematic review described the effect of HA alone as more pronounced than that of cocktail preparations, a comparison made across studies. Clinical data on the amino acid products are thin: one example is an uncontrolled study, funded by the maker of Sunekos, of 46 women treated for cellulite on the hips, buttocks and thighs.

What to ask before any skinbooster

Which product is it, made of what, and which of the three groups does it belong to? What is the evidence for that product in that area, and who paid for it? How many sessions, and how will the result be judged? What is the registration number, and does it match the register? Fish allergy matters for polynucleotides, and severe allergies, or allergy to lidocaine or bacterial proteins, matter for some HA gels. For dermal fillers in general, the FDA notes that safety in pregnancy and breastfeeding is unknown.

A skinbooster answers a question about skin quality. Whether that is the question the skin is asking is settled by examining it, and no product name can do that.

Common questions

What is the difference between Profhilo and Rejuran?

Profhilo is hyaluronic acid of two molecular weights, which its maker describes as stabilised by heat rather than by a chemical cross-linker. Rejuran is a polynucleotide product, made of purified DNA fragments that are usually taken from salmon or trout. They are different substances with different evidence, so the useful questions are what each is described for and what the trials show in the area being treated.

Is Skinvive the same as Juvéderm Volite?

According to the FDA's summary, Skinvive by Juvéderm is marketed as Juvéderm Volite outside the United States, so the two names refer to one product. The Malaysian register lists it as Skinvive by Juvéderm. It is cross-linked hyaluronic acid at 12 mg/mL with a little lidocaine, and its US approval is for improving the smoothness of the cheeks in adults over 21.

Do skinbooster injections have good evidence behind them?

The evidence is limited. A 2023 systematic review of 13 studies found improvement in hydration, firmness and texture with injectable hyaluronic acid and called for large randomised trials. The trials that exist are small or short, several were funded by the makers, and the evidence for polynucleotides and cocktail products is thinner. What a product does for a particular person's skin is decided at assessment.

Sources

  1. FDA Summary of Safety and Effectiveness Data, PMA P110033/S059, SKINVIVE by JUVEDERM, approved 11 May 2023 Indicated for intradermal injection to improve skin smoothness of the cheeks in adults over 21; HA cross-linked with BDDE with 0.3% lidocaine; marketed as Juvederm Volite outside the United States; the pivotal study (209 randomised, SKINVIVE or delayed-treatment control, evaluator-blind, run by the applicant); contraindications (severe allergy, bacterial protein allergy, lidocaine allergy); modified ITT analysis 202 participants (131 treated, 71 control); treatment-group responder rate 55.6% (69/124, observed data) at month 6, with no control comparison after month 1 because controls were offered treatment.
  2. Alexiades M, Palm MD, Kaufman-Janette J, Papel I, et al. A randomized, multicenter, evaluator-blind study to evaluate the safety and effectiveness of VYC-12L treatment for skin quality improvements. Dermatol Surg 2023;49:682-688 Responder rates 57.9% and 58.3% against 4.5% and 5.4% in untreated controls at month 1, consistent through the 6-month follow-up.
  3. Medical Device Authority, Malaysia. Malaysia Medical Device Register (MMDR), public search, entries opened 30 September 2026 (data updated 29 September 2026) Registered descriptions: Skinvive by Juvederm (cross-linked HA, 12 mg/mL, intradermal); Restylane Skinboosters Vital (stabilised HA of non-animal origin, dermal layer); Profhilo (highly purified sodium hyaluronate of two molecular weights, 32 mg + 32 mg per 2 mL), Profhilo Structura (45 mg + 45 mg per 2 mL, HA obtained by biofermentation without chemical modification); Rejuran (highly purified sodium polynucleotides, 20 mg/mL, mid to deep dermis) and Rejuran HB Plus (polynucleotide with HA); Plinest (polynucleotides extracted from fish); Nucleofill (polymerised polynucleotides); NCTF 135 HA (free, non-cross-linked HA in a solution called NCTF); Sunekos and Jalupro (sodium hyaluronate with amino acids). All are listed as medical devices.
  4. Scrima M, Merola F, Vito N, Pacchioni D, et al. Elucidations on the performance and reversibility of treatment with hyaluronic acid based dermal fillers: in vivo and in vitro approaches. Clin Cosmet Investig Dermatol 2022;15:2629-2640 Describes Profhilo and Profhilo Structura as thermally stabilised hybrid complexes of high and low molecular weight HA, a different chemical class from cross-linked HA. Used for classification only: all authors work for the maker (IBSA), and its animal and laboratory findings are not used.
  5. Zanella G, de Souza Ataide FT, de Lima Bonato TC, Cordeiro JM, et al. Effects of Profhilo Tissue Bioremodeling on skin texture and perioral wrinkles: a randomized controlled triple-blind clinical trial. Aesthet Plast Surg 2026;50:4324-4332 12 women aged 45 to 65, split-face against saline, two sessions 30 days apart, assessed at 60 days: wrinkles and pores improved on stereophotogrammetry, dermal thickness rose on both sides (Profhilo p = 0.016, saline p < 0.001), and the authors conclude that the effect on thickness did not exceed the placebo effect and that patients were not fully satisfied with the outcomes. Two letters to the editor comment on this trial (PMIDs 41954642 and 42410190); their text was not accessible and was not read. The abstract also gives satisfaction percentages (36.4% and 54.5%) that do not divide evenly into 12; the full text is paywalled, so the article does not quote them.
  6. de Wit A, Siebenga PS, Wijdeveld RW, Koopmans PC, et al. A split-face comparative performance evaluation of injectable hyaluronic acid-based preparations HCC and CPM-HA20G in healthy females. J Cosmet Dermatol 2022;21:5576-5583 24 women, split-face, three injection sessions, follow-up to week 14: both products improved hydration and elasticity and there were no significant differences between them.
  7. Ghatge AS, Ghatge SB. The effectiveness of injectable hyaluronic acid in the improvement of the facial skin quality: a systematic review. Clin Cosmet Investig Dermatol 2023;16:891-899 13 studies (8 of HA alone, 5 of HA cocktails): improvement in hydration, firmness, texture, radiance and elasticity; the effect of HA alone was more pronounced than that of the cocktail ingredients; large randomised trials are required.
  8. Alhussain AM, Turki M Albusayys S, Alfhadi MA, Bu Mozah SA, et al. Polynucleotides and polydeoxyribonucleotides for skin rejuvenation, postoperative scar prevention, and wound healing: a systematic review of randomized clinical trials. Cureus 2026;18:e112403 Seven trials, 183 participants; four in skin rejuvenation (split-face and parallel designs of 10 to 29 participants: PN with radiofrequency microneedling against microneedling alone; PDRN with microneedling against PRP with microneedling; needle against needle-free injection of PN; an ionisation-adjusted PN filler against a conventional one); no serious treatment-related adverse events; small samples, heterogeneous protocols, variable outcome measures; larger trials needed.
  9. Arora G. Polynucleotides and polydeoxyribonucleotides in dermatology: a narrative review. J Cutan Aesthet Surg 2026;19:17-28 PN as the wider group and PDRN as a subset; mostly salmon gonads or rainbow trout; proposed mechanisms (adenosine A2A receptor binding, salvage pathway) supported by many in vitro studies on cultured cells and, the review says, confirmed in vivo on humans as well; no standardised protocol; inter-batch variability from the same source; no data on long-term evaluation; fish hypersensitivity caution (not all fish-allergic patients react; patch testing may help); more controlled trials needed.
  10. Prikhnenko S. Polycomponent mesotherapy formulations for the treatment of skin aging and improvement of skin quality. Clin Cosmet Investig Dermatol 2015;8:151-157 NCTF as an example of a polycomponent formulation containing vitamins, minerals, amino acids, nucleotides, coenzymes, antioxidants and HA; the rationale rests on in vitro experiments. Disclosure read: medical writing assistance for the review was supported by Filorga Laboratories, the company that markets NCTF; the constituent table comes from the company's product information.
  11. Fanian F, Deutsch JJ, Bousquet MT, Boisnic S, et al. A hyaluronic acid-based micro-filler improves superficial wrinkles and skin quality: a randomized prospective controlled multicenter study. J Dermatolog Treat 2023;34:2216323 NCTF 135HA: 146 randomised (107 injected plus cream, 38 cream alone), superficial wrinkles reduced at day 75 and day 120 compared with the control; the control group had cream alone (no injected placebo); funded by Laboratoires FILLMED.
  12. Fasola E, Boca A, Reggiardo G, Nobile V, et al. An innovative injection technique for treating edematous fibrosclerotic panniculopathy (cellulite): a prospective multicenter clinical investigation. Aesthet Surg J Open Forum 2026;8:ojag137 An uncontrolled study (level of evidence 4) of 46 women treated for cellulite in the trochanteric-gluteal-femoral area (hips, buttocks, thighs) with a formulation of hyaluronic acid and six amino acids (Sunekos Cell 15); used only to show that clinical data on the HA and amino acid products are thin. Treated area: trochanteric-gluteal-femoral; funded by Professional Dietetics S.p.A., the maker of Sunekos.
  13. Lee BM, Han DG, Choi WS. Rejuvenating effects of facial hydrofilling using Restylane Vital. Arch Plast Surg 2015;42:282-287 30 women, uncontrolled, three sessions: 77% satisfied. Read for completeness; not quoted in the article.
  14. US Food and Drug Administration. Dermal Fillers (Soft Tissue Fillers). Content current as of 7 June 2023 Safety of dermal fillers is unknown in pregnancy and breastfeeding.
  15. Sohu and 21st Century Business Herald (21jingji.com): Chinese-language articles on the nicknames 童颜针, 少女针, 婴儿针 and 三文鱼针. Cited in the Chinese edition In Chinese usage 婴儿针 and 三文鱼针 name products based on PN or PDRN (the salmon reproductive-cell extract); 童颜针 usually PLLA or PDLLA products and 少女针 PCL with CMC. Second source: https://m.21jingji.com/article/20210629/herald/712cf842ca0ba8363b310868e7791b43_zaker.html

If you need more information, you can always contact us.